Nivolumab (Opdivo®) is an anti-programmed death receptor-1 (PD-1) monoclonal antibody checkpoint inhibitor. PD-1 is a negative regulator of T-cell activation and proliferation, meaning it “turns the immune response off,” essentially acting as a brake. This type of inhibition is necessary to prevent excessive immune reaction and autoimmunity. For this reason, PD-1 and other regulators acting in this manner are known as immune checkpoints. We now understand that some tumors can exploit the PD-1 pathway, enabling them to evade an immune response. Nivolumab selectively binds to PD-1, thus blocking the inhibitory pathway, allowing the immune response to occur.

Nivolumab is indicated as monotherapy for the treatment of metastatic NSCLC and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK driver mutations should have disease progression on FDA-approved therapy for these mutations before receiving nivolumab.

This document is part of an overall toolkit intended to assist health care providers in optimizing management of lung cancer in patients receiving newer anti-lung cancer therapies.
For metastatic non-small cell lung cancer, the recommended dosage of nivolumab (Opdivo®) is 240 mg administered as an intravenous infusion over 30 minutes every 2 weeks or 480 mg every 4 weeks until disease progression or unacceptable toxicity.

Nivolumab is a clear to slightly opalescent, colorless to pale-yellow solution. Discard the vial if the solution is cloudy, discolored, or contains extraneous particulate matter (other than a few translucent-to-white, proteinaceous particles).

To prepare the dose, withdraw the required volume of nivolumab and transfer it into an intravenous container. This should be diluted with either 0.9% sodium chloride injection, USP, or 5% dextrose, USP to prepare an infusion with a final concentration ranging from 1 mg/mL to 10 mg/mL.

Mix the diluted solution by gentle inversion. Do not shake.

Do not coadminister nivolumab with other drugs through the same intravenous line.

Nivolumab is classified as an irritant and may be safely administered via a central or peripheral line. It is important to ensure IV access before administration. Nivolumab should be administered through an intravenous line containing a sterile, non-pyrogenic, low-protein-binding in-line or add-on filter (pore size of 0.2-1.2 micrometers).
Because nivolumab is an immunotherapy that works by enhancing the patient’s immune system, most adverse reactions associated with nivolumab are related to overactivity of the patient’s immune system (i.e., immune-related adverse events [irAEs]). Various organ systems (often more than one) or tissues may be affected.

• Keys to toxicity management:
  » Proactive assessment for early signs/symptoms of irAEs
  » Prompt intervention
  » irAEs are typically managed with dose interruption and selective use of corticosteroids
  » In rare instances, toxicity may be steroid refractory, and additional immunosuppressive agents (infliximab, mycophenolate mofetil, cyclophosphamide, etc) may be necessary
  » Nivolumab will likely be held or discontinued depending on the severity and/or persistence of the irAE
  » Referral to organ specialist should be considered, given that unique testing and management strategies may be required

• irAEs associated with nivolumab treatment can be categorized as those that are most common, less common but serious, and others that are easily overlooked

• Table 1 lists these irAEs and the corresponding Care Step Pathways in Appendix 1. Other adverse events associated with nivolumab are shown in Appendix 2

### Table 1. Care Step Pathways for the management of immune-related AEs associated with nivolumab monotherapy.

<table>
<thead>
<tr>
<th>irAE category</th>
<th>Examples</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Most common</td>
<td>Skin toxicities (pruritus, rash, etc)</td>
<td>Appendix 1</td>
</tr>
<tr>
<td></td>
<td>Gastrointestinal toxicity: Diarrhea/colitis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thyroiditis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hepatic toxicities</td>
<td></td>
</tr>
<tr>
<td>Less common but serious</td>
<td>Additional endocrinopathies</td>
<td>Appendix 1</td>
</tr>
<tr>
<td></td>
<td>- Hypophysitis (pituitary)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Adrenal insufficiency</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Diabetes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pneumonitis</td>
<td></td>
</tr>
<tr>
<td>Easily overlooked</td>
<td>Arthralgia/arthritis</td>
<td>Appendix 1</td>
</tr>
<tr>
<td></td>
<td>Mucositis/xerostomia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nephritis</td>
<td></td>
</tr>
</tbody>
</table>
• It is important to monitor laboratory values at the start of treatment, periodically during treatment, and as indicated clinically. Laboratory values commonly monitored include: CBC w/ diff, creatinine, alkaline phosphatase, AST/ALT, bilirubin (direct/total), sodium, potassium, calcium, magnesium, thyroid function, and glucose.

• Determination of programmed cell death ligand 1 (PD-L1) status or elevated expression is not a prerequisite for nivolumab treatment of NSCLC. A survival benefit has been seen with both expressors (PD-L1 positive) and non-expressors (PD-L1 negative).

• Nivolumab-related irAEs may occur at any time, including after treatment completion or discontinuation.

• Patients sometimes experience signs/symptoms that they think are due to “flu” or a cold, but that actually represent an irAE or an infusion reaction.

• Endocrinopathies often present with vague symptoms (fatigue, headache, and/or depression) that can easily be overlooked or initially misdiagnosed. Hypervigilance and follow-up is important on the part of both HCPs and patients.

• Endocrinopathies tend to occur somewhat more commonly with nivolumab or other PD-1 inhibitor therapies than with ipilimumab monotherapy.

• Unlike other irAEs, endocrinopathies usually do not resolve and may require lifelong hormone replacement therapy.

• IrAEs have different time courses. New irAEs may become apparent upon tapering of corticosteroids used to treat an earlier onset irAE, since the new irAE can be suppressed or masked by immunosuppressive therapy. Therefore, during the taper period, patients should be advised to be on the lookout for early signs of new irAEs as well as recurrence of the original irAE that was being treated.

• HCPs should encourage patients to carry information about their nivolumab regimen with them at all times. This might be the nivolumab-specific wallet card, or at least emergency phone numbers and a list of side effects associated with the regimen. You may suggest that they paperclip the wallet and insurance cards together so information about their regimen will be shared whenever they show the insurance card.

• Advise patients to take pictures of any skin changes for documentation.
Q. Is PD-L1 testing required for patients to be eligible to receive nivolumab?

A. PD-L1 testing is recommended for all patients diagnosed with non-small cell lung cancer, preferably at diagnosis. However, PD-L1 testing is not required to receive treatment with nivolumab. However, PD-L1 testing is not required to receive treatment with nivolumab as survival benefit has been seen with both expressors (PD-L1 positive) and non-expressors (PD-L1 negative).

Q. Are there standard dosage reductions for irAEs associated with nivolumab?

A. There are no dosage reductions for irAEs associated with nivolumab. The dose is either held until the irAE resolves sufficiently (typically to Grade 0 or Grade 1) or, if the irAE is severe enough, nivolumab is discontinued permanently.

Q. Does the safety profile of nivolumab vary when used in different tumor types?

A. Generally, the safety profile of nivolumab is similar across tumor types. However, the context may be different—patients with other tumor types may have differing comorbidities or underlying organ dysfunction. For example, lung cancer patients may have underlying lung disease that will exacerbate shortness of breath associated with pneumonitis.

Q. How do I counsel my patients about immunizations?

A. That’s a logical question, given that the checkpoint inhibitors alter the immune response. Advise your patients not to receive live vaccines (eg, measles, mumps, and rubella and the varicella vaccine) because they have not been evaluated in this setting. The use of attenuated vaccines has been and continues to be evaluated. Counsel patients to discuss all immunizations with the oncology team prior to administration so the benefits and risks can be weighed on an individual basis. For example, SHINGRIX®, approved in 2017, is an attenuated (non-live) varicella vaccine; its use can be discussed with the oncology team if a recommendation is being made for the patient to receive the injection series. Annual influenza vaccination with the inactivated influenza vaccine is recommended. The nasal spray flu vaccine is a live attenuated influenza vaccine and should not be administered to patients treated with immune checkpoint inhibitors.
PATIENT RESOURCES

Financial Assistance
BMS Access Support
1 (800) 861-0048
http://www.bmsaccesssupport.bmscustomerconnect.com/patient

Additional Information Resources
Bonnie J. Addario Lung Cancer Foundation
http://www.lungcancerfoundation.org

Lung Cancer Alliance
https://lungcanceralliance.org/resources-and-support/general-support/educational-materials/

American Cancer Society Resource Section
ADDITIONAL RESOURCES


Continue on next page

• Opdivo patient alert card (wallet card) and other resources. http://www.opdivo.com/servlet/servlet.FileDownload?file=00P1Y00000v60IZUAY


APPENDIX 1
The 12 Care Step Pathways (CSPs) referenced in this Appendix are housed in the CSP section of the AIMWithImmunotherapy.com IO Essentials website. These CSP are currently universally applicable (i.e., they don’t differ across tumor types).

Please click the link below to access the CSPs, which can also be printed from that section of the site.

http://aimwithimmunotherapy.org/care-step-pathways/
APPENDIX 2
### Management of other AEs associated with nivolumab monotherapy.

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>Common symptoms</th>
<th>Common management/anticipatory guidance</th>
</tr>
</thead>
</table>
| **Anorexia**                       | Decreased appetite                                       | • Monitor weight; query patient about appetite/eating habits; advise dietary modification if necessary (should improve with time)  
• Anticipate standard dose holds/discontinuations*  
• Consider referral to nutrition services for counseling on best food choices to avoid excessive weight loss |
| **Constipation/abdominal pain**    | Infrequent stools/difficulty stooling, abdominal pain    | • Consider other causes, such as opioid-induced constipation  
• Increase fluid, fiber; use laxatives with caution; suggest stool softeners and increased physical activity  
• Consider appropriate testing to evaluate bowel obstruction  
• Anticipate standard dose holds/discontinuations* for Grade 3 and Grade 4 (constipation with manual evacuation indicated, severe abdominal pain, or life-threatening consequences) |
| **Embryo-fetal toxicity**          | —                                                        | • Advise patients to tell their HCPs immediately if they or their partners suspect they are pregnant while taking therapy  
• Advise patient to tell HCP immediately if they or their partner suspect they are pregnant while taking therapy |
| **Encephalitis**                   | Headache, fever, tiredness, confusion, memory problems, sleepiness, hallucinations, seizures, stiff neck | • New-onset, moderate-to-severe symptoms: rule out infectious or other causes  
• Counsel neurologist, obtain brain MRI, and lumbar puncture  
• Anticipate standard dose-holds and discontinuations* |
| **Fatigue**                        | Feeling tired; lack of energy                            | • Query patients regarding energy level; evaluate possible contributory factors, including infection, disease progression, and hematological and metabolic abnormalities; standard supportive care  
• Anticipate standard dose holds/discontinuations*  
• Fatigue that interferes with ADLs is concerning and should be evaluated for underlying causes, such as possible endocrinopathy |
| **Headache**                       | Head pain                                                | • Need to rule out brain metastases, encephalitis, or hypophysitis; otherwise, standard supportive care (should improve with time)  
• Headache occurring in conjunction with fatigue could be indicative of hypophysitis; obtain MRI of brain with pituitary slices/pituitary protocol to confirm/rule out.  
• Anticipate standard dose holds/discontinuations* |
## Management of other AEs associated with nivolumab monotherapy.
(Continued)

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>Common symptoms</th>
<th>Common management/anticipatory guidance</th>
</tr>
</thead>
</table>
| Infusion reaction     | Chills/shaking, back pain, itching, flushing, difficulty breathing, hypotension, fever                  | • For mild/moderate (Grade 1-2) reactions: interrupt or slow rate of infusion; monitor to recovery  
  • For severe/life-threatening (Grade 3-4) reactions: discontinue nivolumab; manage anaphylaxis via institutional protocol; monitor. Premedication with an antipyretic and antihistamine may be considered for future doses |
| Insomnia              | Difficulty falling or staying asleep                  | • Counsel patients on good sleep habits; prescription medications can be used if needed (should improve over time)  
  • Anticipate standard dose holds/discontinuations* |
| Myocarditis           | Shortness of breath; arrhythmia; light-headedness; chest pain; fatigue; nausea; edema                   | • Obtain baseline ECG  
  • Assess cardiac biomarkers (BNP; troponin)  
  • Control cardiac diseases (and risk factors) optimally  
  • Consult cardiologists and consider corticosteroids if myocarditis is suspected  
  • Add additional immunosuppressive agents in severe, refractory cases  
  • Institute standard dose holds/discontinuations (in consultation with cardiologist) |
| Nausea/vomiting       | Vomiting, queasiness, RUQ or LUQ pain                 | • Rule out brain metastases and gastroenteritis  
  • Provide standard supportive care, since it is adequate in most cases  
  • Check LFTs/lipase/amylase if hepatotoxicity or pancreatitis is suspected  
  • Anticipate standard dose holds/discontinuations* |
| Upper respiratory tract infection | Cough, runny nose, sore throat, nasal congestion | • Evaluate potential causes—a dry cough and shortness of breath would increase concern for pneumonitis  
  • Standard supportive care  
  • Anticipate standard treatment holds* |
| Vision changes        | Eye redness, pain, blurred vision, photophobia       | • Test and evaluate for uveitis and episcleritis (by ophthalmologist, preferably)  
  • Urgency of ophthalmology referral increases with grade  
  • G1: continue immunotherapy, use artificial tears  
  • G2: hold immunotherapy; ophthalmic and systemic corticosteroids (under ophthalmologist guidance)  
  • G3 or G4: permanently discontinue immunotherapy; treatment by ophthalmologist to include ophthalmic and systemic corticosteroids |

*Withhold nivolumab for any Grade 3 (severe) AE. Permanently discontinue for any Grade 4 (life-threatening) AE, persistent Grade 2-3 AE, any severe (Grade 3) AE that recurs, or when ≥10 mg/d prednisone or equivalent is required for 12 weeks. Resume treatment when AE returns to Grade 0 or 1.